Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Research from University of Otago reveals new findings on breast cancer
November 20th, 2008
"We have previously shown that tamoxifen + epigallocatechin gallate (EGCG) is synergistically cytotoxic towards oestrogen receptor (ER)-negative breast cancer cells. To determine if this response would correlate with significant tumour suppression in vivo, athymic nude female mice were implanted with MDA-MB-231 cells and treated with tamoxifen, EGCG, EGCG + tamoxifen, or vehicle control for 10 weeks," researchers in Dunedin, New Zealand report. "Tumour volume in EGCG-(25 mg kg(-1)) + tamoxifen (75 mg kg(-1))-treated mice decreased by 71% as compared with vehicle control (P <0.05), whereas tumour weight was decreased by 80% compared with control (P <0.01)....
Source: Women's Health Weekly (2008-11-20)
|
